Form 8-K - Current report:
SEC Accession No. 0001193125-24-250965
Filing Date
2024-11-05
Accepted
2024-11-05 07:10:52
Documents
14
Period of Report
2024-11-05
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d875236d8k.htm   iXBRL 8-K 23573
2 EX-99.1 d875236dex991.htm EX-99.1 25748
  Complete submission text file 0001193125-24-250965.txt   180022

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA itci-20241105.xsd EX-101.SCH 2896
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE itci-20241105_lab.xml EX-101.LAB 17995
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE itci-20241105_pre.xml EX-101.PRE 11292
16 EXTRACTED XBRL INSTANCE DOCUMENT d875236d8k_htm.xml XML 3615
Mailing Address 135 ROUTE 202/206 SUITE 6 BEDMINSTER NJ 07921
Business Address 135 ROUTE 202/206 SUITE 6 BEDMINSTER NJ 07921 (646) 440-9333
Intra-Cellular Therapies, Inc. (Filer) CIK: 0001567514 (see all company filings)

EIN.: 364742850 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36274 | Film No.: 241425606
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)